

2012-2013

President Bryan R. Haugen, M.D. (2012-2013) Denver, Colorado

Secretary/Chief Operating Officer John C. Morris, M.D. (2011-2015) Rochester, Minnesota

Treasurer David H. Sarne, M.D. (2007-2013) Chicago, Illinois

President-Elect Hossein Gharib, M.D. (2012-2013) Rochester, Minnesota

Treasurer-Elect Gregory W. Randolph, M.D. (2012-2013) Boston, Massachusetts

Past-President James A. Fagin, M.D. (2012-2013) New York, New York

Directors

Peter A. Kopp, M.D. (2009-2013) Chicago, Illinois

Elizabeth N. Pearce, M.D. (2009-2013) Boston, Massachusetts

Victor J. Bernet, M.D. (2010-2014) Jacksonville, Florida

Gerard M. Doherty, M.D. (2010-2014) Boston, Massachusetts

Sissy M. Jhiang, Ph.D. (2010-2014) Columbus, Ohio

Erik K. Alexander, M.D. (2011-2015) Boston, Massachusetts

Martha A. Zeiger, M.D. (2011-2015) Baltimore, Maryland


James V. Hennessey, M.D. (2012-2016) Boston, Massachusetts

Susan A. Sherman, M.D. (2012-2016) Aurora, Colorado

Executive Director Barbara R. Smith, CAE

Headquarters' Office

American Thyroid Association6066 Leesburg Pike, Suite 550Falls Church, Virginia 22041Phone:703 998-8890Fax:703 998-8893E-mail:bsmith@thyroid.orgWeb:www.thyroid.org



Dear Colleagues,

I am pleased to welcome you to the ATA Spring Symposium and Research Summit on "Treatment of Hypothyroidism: Exploring the Possibilities."

On behalf of the American Thyroid Association (ATA) Board of Directors, we would like to express our appreciation for your presence here at the Westin Washington, DC City Center Hotel.

We will have many opportunities to share our understanding of how the latest basic and clinical research in thyroid hormone metabolism, transport, and action translates into recommendations for clinicians managing hypothyroid patients.

We will explore both the role of traditional thyroid hormone replacement therapy and alternatives to the use of levothyroxine alone. You are joining thought leaders and decision makers from the most prestigious medical institutions in North America and around the world, including top academic research scientists and clinical scientists and investigators.

On the research summit day, Thursday the 25th of April, experts in the field from North America and Europe will present and discuss recent studies on basic principles of thyroid hormone homeostasis and action.

The clinical symposium on Friday the 26th of April will re-examine the evidence concerning alternatives therapies other than levothyroxine, to discuss gaps in our current knowledge of these therapies, and to determine whether new data provides reason to pursue these therapies. We will review the goals of levothyroxine therapy and examine the latest data regarding combination therapy, thyroid hormone analogs, and the potential for genetic variations to influence thyroid hormone therapy.

Please introduce yourself to me and let me know how we can improve the meeting experience and the ATA member experience. We also invite you to join the ATA if you are not already a member. We have much to offer and would enjoy your active participation in our work.

On behalf of the ATA members and the ATA Board of Directors, we welcome you.

Best regards,

Bryan R. Haugen, MD President, American Thyroid Association